# US 2024/0199692 A1 · Polypeptide having mmp2-inhibitory effect

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199692 A1
- Document ID: US20240199692A1
- Status: Published application
- Kind: A1
- Application number: 17/774,993
- Filed: 2020-11-06
- Published: 2024-06-20
- Earliest claimed: 2019-11-08
- Assignees: Taisho Pharmaceutical Co., Ltd.
- Applicants: Taisho Pharmaceutical Co., Ltd.
- Inventors: Masato HAYASHI; Tomoki TAKEUCHI; Yusaku NOMURA; Tomoko TAMITA; Rie SHIMONO
- Web page: https://patentgrep.com/patent/US20240199692A1

## CPC

- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/07: Tetrapeptides
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 5/0215: {containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu}
- C12N 9/99: Enzyme inactivation by chemical treatment
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a substituted polypeptide having the effect of inhibiting MMP2 and represented by formula [I′], or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A substituted polypeptide represented by formula [I′]:
or a pharmaceutically acceptable salt thereof,
wherein
AA1 represents:
Asp,
β-Asp, β-(d)-Asp, γ-Glu, or γ-(d)-Glu;
AA2 represents one group selected from the group consisting of:
Ala,
a group represented by any of formulas [IV-7], [IV-8], [IV-9], [IV-11], [IV-12], and [IV-13]:
a group represented by formula [IV-27]:
Pro, and a group represented by any of formulas [II-1] and [II-2]:
wherein RAA2 represents hydroxy or amino;
AA1 and AA2 may be taken together to form a structure represented by formula [IV-32]:
AA3 represents one group selected from the group consisting of:
Val, Leu, Ile, a group represented by formula [IV-2]:
Phe, Trp,
Tyr, Lys, a group represented by any of formulas [IV-3], [IV-4], and [IV-5]:
and
a group represented by formula [IV-9]:
AA4 represents one group selected from the group consisting of:
a single bond,
Gly, (d)-Ala, (N-Me)Ala, (N-Me)Val, (N-Me)Leu, (N-Me)Ile,
Pro, (d)-Pro,
(N-Me)Phe, (d)-Phe,
(N-Me)Tyr, (d)-Tyr,
(N-Me)Ser, (d)-Ser, homoSer, (d)-Thr,
Met, (N-Me)Met,
(N-Me)Asp, Glu, (N-Me)Glu, (d)-(N-Me)Glu, homoGlu,
(N-Me)Asn,
(N-Me)Arg, (d)-Arg,
a group represented by any of formulas [IV-7], [IV-9], and [IV-13]:
Lys, and (N-Me)Lys,
wherein if AA4 represents Lys, then
the amino in the side chain of the Lys is optionally substituted with C2-16 alkylcarbonyl terminally-substituted with carboxy;
AA5 represents one group selected from the group consisting of:
a single bond,
Ala, a group represented by formula [IV-1]:
a group represented by any of formulas [IV-27], [IV-28], and [IV-29]:
Pro, (d)-Pro, β-homoPro, homoPro, a group represented by formula [II-1′]:
Phe, His,
Thr,
Arg, (d)-Arg,
a group represented by any of formulas [IV-7], [IV-9], and [IV-13]:
Lys, (d)-Lys,
β-Ala, (N-Me)-β-Ala, GABA, Ape, Acp,
a group represented by any of formulas [III-6] to [III-13]:
and
a group represented by any of formula [IV-25] and [IV-26]:
W1 represents -L1- or -L1′-L1″-; wherein
L1 represents a single bond; and
L1′ represents one group selected from the group consisting of:
a single bond,
β-Ala, GABA, (N-Me)GABA, Ape, Acp,
a group represented by any of formulas [III-6] to [III-13]
and
a group represented by any of formulas [IV-23] and [IV-24]:
and
L1″ represents one group selected from the group consisting of:
a single bond,
Gly, (N-Me)Gly,
Ala, (N-Me)Ala, (d)-Ala, Val, (N-Me)Val, (N-Me)Leu, (N-Me)Ile,
a group represented by formula [IV-27]:
Pro, (d)-Pro, homoPro, Phe, (N-Me)Phe, (d)-Phe,
His, (d)-His, Trp, (N-Me)Trp, (d)-Trp,
Tyr, (N-Me)Tyr, (d)-Tyr,
(d)-Ser, homoSer, Thr, (N-Me)Thr, (d)-Thr,
Cys, (d)-Cys, Met, (N-Me)Met,
(N-Me)Asp, Glu, (N-Me)Glu, (d)-Glu,
Asn, (N-Me)Asn, (d)-Asn, Gln, (N-Me)Gln, (d)-Gln,
Arg, (N-Me)Arg, (d)-Arg, Cit, (d)-Cit,
a group represented by any of formulas [IV-7], [IV-9], [IV-10], and [IV-13]:
Lys, (N-Me)Lys, (d)-Lys, a group represented by formula [IV-14]:
β-Ala,
β-Asp, β-(d)-Asp, and
a group represented by any of formulas [III-6] and [III-7]:
wherein if L1″ represents Lys or (d)-Lys, then
the amino in the side chain of the Lys or (d)-Lys is optionally substituted with a group represented by formula [VII-1]:
FAN-AAN5-AAN4-AAN3-AAN2-AAN1- [VII-1]
wherein
FAN represents C2-16 alkylcarbonyl terminally-substituted with carboxy;
AAN5 represents:
a single bond,
Arg, (d)-Arg,
Lys, (d)-Lys,
γ-Glu, or
a group represented by formula [IV-24]:
AAN4 represents:
a single bond,
Arg, (d)-Arg,
Lys, (d)-Lys, or
a group represented by formula [IV-24]:
AAN3 represents:
a single bond,
Arg, (d)-Arg,
Lys, (d)-Lys,
γ-Glu, or
a group represented by formula [IV-24]:
AAN2 represents:
a single bond, or
(d)-Lys; and
AAN1 represents:
a single bond, or
(d)-Lys;
wherein if L1″ represents by Glu and AA3 represents Lys, then
the compound represented by formula [I′] may be taken together with L3 attached to each of functional groups in the side chains of the two amino acids to form a cyclic structure, as represented by formula [I′-α]:
wherein the L3 represents Gly, β-Ala, or GABA;
LN1 represents the formula —C(═O)— or the formula —S(═O)2—;
LN2 represents:
a single bond,
C1-3 alkanediyl,
C2-3 alkenediyl,
ethynediyl,
the formula —O—,
the formula —C(═O)—, the formula —C(═O)—NH—, or
triazolediyl;
L2 represents a single bond;
ring A represents an aromatic ring or a heteroaromatic ring;
RA1 and RA2 each independently represent:
a hydrogen atom,
a halogen atom,
C1-6 alkyl, or
C1-6 alkoxy;
ring B represents:
aryl or heteroaryl;
RB1, RB2, and RB3 each independently represent:
a hydrogen atom,
carbamoyl,
cyano,
a halogen atom,
C1-6 alkyl optionally substituted with one hydroxy, halo C1-6 alkyl,
C1-6 alkoxy optionally substituted with one hydroxy, halo C1-6 alkoxy,
C1-6 alkylcarbonyl,
C1-6 alkylcarbonylamino,
mono C1-6 alkylaminocarbonyl, di C1-6 alkylaminocarbonyl, wherein the alkyl in each of the mono C1-6 alkylaminocarbonyl and the di C1-6 alkylaminocarbonyl is optionally substituted with one group selected from the group consisting of hydroxy, carboxy, carbamoyl, and amino,
C1-6 alkylsulfonyl, or
aryl;
WC is a single bond or a linker consisting of one to three amino acids, wherein the one to three amino acids forming the linker are same or different and each selected from the group consisting of:
Gly,
Pro,
Arg, (d)-Arg,
Lys, (d)-Lys,
β-Ala, GABA, and Ape,
wherein if Lys or (d)-Lys is included in the group represented by WC, then
the amino in the side chain of the Lys or (d)-Lys is optionally substituted with:
C2-16 alkylcarbonyl terminally-substituted with carboxy,
Lys, wherein the amino in the side chain of the Lys is optionally substituted with C2-16 alkylcarbonyl terminally-substituted with carboxy, or
(d)-Lys, wherein the amino in the side chain of the (d)-Lys is optionally substituted with C2-16 alkylcarbonyl terminally-substituted with carboxy; and
RC is:
the formula —OH, the formula —NH2,
C1-6 alkylamino, wherein the C1-6 alkyl of the C1-6 alkylamino is optionally substituted with one group selected from the group consisting of hydroxy, amino, C1-6 alkoxy, and four- to seven-membered saturated heterocyclyl containing one nitrogen atom and optionally further containing one heteroatom, or
four- to seven-membered saturated heterocyclyl containing one nitrogen atom and optionally further containing one heteroatom; wherein the four- to seven-membered saturated heterocyclyl containing one nitrogen atom and optionally further containing one heteroatom is optionally substituted with one group selected from the group consisting of hydroxy, amino, and C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with one carbamoyl; and two carbon atoms in the four- to seven-membered saturated heterocyclyl containing one nitrogen atom and optionally further containing one heteroatom are optionally crosslinked with C1-4 alkanediyl.

### Claim 2 (depends on 1)

The substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein
WC is:
a single bond,
Pro,
Arg, (d)-Arg,
Lys, (d)-Lys,
β-Ala, GABA, Ape,
Gly-(d)-Lys, Gly-(d)-Lys-(d)-Lys, Gly-(d)-Lys-(d)-Arg, Gly-(d)-Arg-(d)-Lys,
Lys-Lys, (d)-Lys-(d)-Lys, (d)-Lys-(d)-Lys-(d)-Lys,
Arg-Arg, (d)-Arg-(d)-Arg, (d)-Arg-(d)-Lys,
Lys-(d)-Lys-(d)-Lys, (d)-Lys-Lys-(d)-Lys, (d)-Lys-(d)-Lys-Lys,
β-Ala-(d)-Lys, β-Ala-(d)-Lys-(d)-Arg,
β-Ala-(d)-Arg-(d)-Lys, or β-Ala-(d)-Arg-(d)-Arg,
wherein if Lys is contained in the group represented by WC, then
the amino in the side chain of the Lys is optionally substituted with:
C2-16 alkylcarbonyl terminally-substituted with carboxy, or
(d)-Lys, wherein the amino in the side chain of the (d)-Lys is optionally substituted with C2-16 alkylcarbonyl terminally-substituted with carboxy.

### Claim 3 (depends on 1)

The substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein
ring A is a benzene ring, a thiophene ring, or a pyridine ring;
RA1 and RA2 are each independently:
a hydrogen atom, or
a halogen atom;
ring B is:
phenyl, oxazolyl, thiadiazolyl, pyridyl, or benzofuranyl;
RB1, RB2, and RB3 are each independently:
a hydrogen atom,
carbamoyl,
cyano,
a halogen atom,
C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with one hydroxy,
halo C1-6 alkyl,
C1-6 alkoxy, wherein the C1-6 alkoxy is optionally substituted with one hydroxy,
halo C1-6 alkoxy,
C1-6 alkylcarbonyl,
mono C1-6 alkylaminocarbonyl, di C1-6 alkylaminocarbonyl, wherein the alkyl in each of the mono C1-6 alkylaminocarbonyl and the di C1-6 alkylaminocarbonyl is optionally substituted with one group selected from the group consisting of hydroxy, carboxy, carbamoyl, and amino, or
C1-6 alkylsulfonyl; and
RC is:
the formula —OH, the formula —NH2,
C1-6 alkylamino, wherein the C1-6 alkyl of the C1-6 alkylamino is optionally substituted with one group selected from the group consisting of hydroxy, amino, C1-6 alkoxy, and morpholinyl,
azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl, wherein the azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl is optionally substituted with one group selected from the group consisting of hydroxy, amino, and C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with one carbamoyl, wherein
two carbon atoms in the azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl are optionally crosslinked with C1-4 alkanediyl.

### Claim 4 (depends on 1)

The substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein in the substituted polypeptide represented by formula [I′],
ring A is a benzene ring;
ring B is phenyl;
L1″ is one group selected from the group consisting of:
a single bond,
Gly, (N-Me)Gly,
Ala, (N-Me)Ala, (d)-Ala, Val, (N-Me)Val, (N-Me)Leu, (N-Me)Ile,
a group represented by formula [IV-27]:
Pro, (d)-Pro, homoPro, Phe, (N-Me)Phe, (d)-Phe,
His, (d)-His, Trp, (N-Me)Trp, (d)-Trp,
Tyr, (N-Me)Tyr, (d)-Tyr,
(d)-Ser, homoSer, Thr, (N-Me)Thr, (d)-Thr,
Cys, (d)-Cys, Met, (N-Me)Met,
(N-Me)Asp, Glu, (N-Me)Glu, (d)-Glu,
Asn, (N-Me)Asn, (d)-Asn, Gln, (N-Me)Gln, (d)-Gln,
Arg, (N-Me)Arg, (d)-Arg, Cit, (d)-Cit,
a group represented by any of formulas [IV-7], [IV-9], [IV-10], and [IV-13]:
Lys, (N-Me)Lys, (d)-Lys, a group represented by formula [IV-14]:
β-Ala,
β-Asp, β-(d)-Asp, and
a group represented by any of formulas [III-6] and [III-7]:
WC is:
a single bond,
Pro,
Arg, (d)-Arg,
Lys, (d)-Lys,
β-Ala, GABA, Ape,
Gly-(d)-Lys, Gly-(d)-Lys-(d)-Lys, Gly-(d)-Lys-(d)-Arg, Gly-(d)-Arg-(d)-Lys,
Lys-Lys, (d)-Lys-(d)-Lys, (d)-Lys-(d)-Lys-(d)-Lys,
Arg-Arg, (d)-Arg-(d)-Arg, (d)-Arg-(d)-Lys,
Lys-(d)-Lys-(d)-Lys, (d)-Lys-Lys-(d)-Lys, (d)-Lys-(d)-Lys-Lys,
β-Ala-(d)-Lys, β-Ala-(d)-Lys-(d)-Arg,
β-Ala-(d)-Arg-(d)-Lys, or β-Ala-(d)-Arg-(d)-Arg.

### Claim 5 (depends on 1)

The substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein in the substituted polypeptide represented by formula [I′],
AA2 is one group selected from the group consisting of:
a group represented by formula [II-1]:
and
a group represented by any of formulas [IV-7], [IV-8], [IV-9], [IV-11], and [IV-12]:
wherein RAA2 is amino;
AA3 is Val, Leu, Ile, Phe, or Trp;
AA4 is (N-Me)Val, (N-Me)Leu, (N-Me)Ile, (N-Me)Asp, or (N-Me)Glu;
AA5 is β-Ala, GABA, Ape, Acp, Pro, (d)-Pro, or β-homoPro;
WC is a single bond, Arg, (d)-Arg, Lys, or (d)-Lys; and
RC is the formula —OH or the formula —NH2.

### Claim 6 (depends on 1)

The substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein in the substituted polypeptide represented by formula [I′],
W1 is -L1′-L1″-;
L2 is a single bond;
AA1 is Asp;
L1′ is one group selected from the group consisting of β-Ala, GABA, Ape, Acp, and a group represented by any of formulas [IV-23] and [IV-24]:
L1″ is a single bond, Asn, (d)-Ser, (d)-Thr, or Glu;
LN1 is the formula —C(═O)— or the formula —S(═O)2—;
LN2 is the formula —O— or the formula —C(═O)—NH—;
RA1 and RA2 are each a hydrogen atom; and
RB1, RB2, and RB3 are each independently a hydrogen atom, carbamoyl, a halogen atom, C1-6 alkoxy, or halo C1-6 alkoxy.

### Claim 7 (depends on 1)

The substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein in the substituted polypeptide represented by formula [I′],
W1 is -L1-, wherein L1 is a single bond;
L2 is a single bond;
AA1 is β-Asp, β-(d)-Asp, γ-Glu, or γ-(d)-Glu;
AA2 is one group selected from the group consisting of:
a group represented by formula [II-1]:
and
a group represented by any of formulas [IV-7], [IV-8], [IV-9], [IV-11], and [IV-12]:
wherein RAA2 is amino;
AA3 is Val, Leu, Ile, Phe, or Trp;
AA4 is (N-Me)Val, (N-Me)Leu, (N-Me)Ile, (N-Me)Asp, or (N-Me)Glu;
AA5 is β-Ala, GABA, Ape, Acp, or β-homoPro;
LN1 is the formula —C(═O)— or the formula —S(═O)2—;
LN2 is a single bond, the formula —O—, or the formula —C(═O)—NH—;
RA1 and RA2 are each a hydrogen atom; and
RB1, RB2, and RB3 are each independently a hydrogen atom, carbamoyl, a halogen atom, C1-6 alkoxy, or halo C1-6 alkoxy.

### Claim 8 (depends on 1)

The substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein the substituted polypeptide represented by formula [I′] is a substituted polypeptide represented by formula [I]:
wherein
AA1 is β-Asp, γ-Glu, or γ-(d)-Glu;
AA2 is a group represented by formula [II-1] or formula [II-2]:
wherein RAA2 is hydroxy or amino;
AA3 is Val, Leu, Ile, Phe, or Trp;
AA4 is a single bond, Pro, (N-Me)Ala, (N-Me)Val, (N-Me)Leu, (N-Me)Ile, (N-Me)Phe, (N-Me)Tyr, (N-Me)Ser, (N-Me)Asp, or (N-Me)Glu;
AA5 is a single bond, Pro, (d)-Pro, β-homoPro, Arg, (d)-Arg, Lys, (d)-Lys, β-Ala, GABA, Ape, or Acp;
L1 is a single bond;
L2 is a single bond;
LN1 is the formula —C(═O)— or the formula —S(═O)2—;
LN2 is a single bond, C1-3 alkanediyl, the formula —O—, or the formula —C(═O)—NH—;
RA is a hydrogen atom, a halogen atom, C1-6 alkyl, or C1-6 alkoxy;
RB is a hydrogen atom, carbamoyl, a halogen atom, C1-6 alkyl, or C1-6 alkoxy;
LC is a single bond, Pro, Arg, (d)-Arg, Lys, (d)-Lys, or (d)-Lys-(d)-Lys; and
RC is the formula —OH or the formula —NH2.

### Claim 9 (depends on 1)

The substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein in the substituted polypeptide represented by formula [I′],
AA1 is Asp, β-(d)-Asp, or γ-(d)-Glu;
AA2 is one group selected from the group consisting of:
a group represented by formula [II-1]:
and
a group represented by any of formulas [IV-7] and [IV-9]:
wherein RAA2 is amino;
AA3 is Val, Leu, or Ile;
AA4 is (N-Me)Ile or (N-Me)Glu;
AA5 is Ape or β-homoPro;
W1 is -L1- or -L1′-L1″-,
wherein
L1 is a single bond,
L1′ is GABA or Ape, and
L1″ is Asn, (d)-Ser, (d)-Thr, or Glu;
LN1 is the formula —C(═O)— or the formula —S(═O)2—;
LN2 is the formula —O— or the formula —C(═O)—NH—;
RA1 and RA2 are each a hydrogen atom;
RB1, RB2, and RB3 are each independently a hydrogen atom, carbamoyl, a halogen atom, C1-6 alkoxy, or halo C1-6 alkoxy;
WC is a single bond or (d)-Lys; and
RC is the formula —NH2.

### Claim 10 (depends on 1)

The substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein the substituted polypeptide is selected from compounds shown in the following:

### Claim 11 (depends on 1)

A pharmaceutical comprising the substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

### Claim 12 (depends on 1)

An MMP2 inhibitor comprising the substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

### Claim 13 (depends on 1)

A drug for preventing or treating cancerous disease or organ fibrosis, or a symptom associated with cancerous disease or organ fibrosis, comprising the substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

### Claim 14 (depends on 1)

A method for inhibiting MMP2 in a subject in need thereof, comprising administering to the subject an effective amount of the substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1.

### Claim 15 (depends on 1)

A method for preventing or treating cancerous disease or organ fibrosis, or a symptom associated with cancerous disease or organ fibrosis in a subject in need thereof, comprising administering to the subject an effective amount of the substituted polypeptide or pharmaceutically acceptable salt thereof according to claim 1.
